Summary
100.32 1.31(1.32%)12/12/2025
Merck & Co., Inc. (MRK)
MRK reported last earnings on 2025-10-30 after the market. An EPS of $2.58 was observed compared to an estimated EPS of $2.36, resulting in a surprise value of $0.22. A revenue of $17,276 million was observed compared to an estimated revenue of $16,978 million, resulting in a surprise value of $298 Million.
Merck & Co., Inc. (MRK)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 1.32 | 10.28 | 19.02 | 24.45 | 37.68 | 6.88 | 61.11 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | A- |
| Recommended Rating | Buy |
| DCF | Strong Buy |
| ROE | Strong Buy |
| ROA | Strong Buy |
| Debt/Equity | Strong Sell |
| P/E | Neutral |
| P/B | Sell |
Earnings
| Trading Data | ||
| Close | 100.32 | |
| Open | 98.75 | |
| High | 100.66 | |
| Low | 98.32 | |
| Volume | 8,927,931 | |
| Change | 1.31 | |
| Change % | 1.32 | |
| Avg Volume (20 Days) | 15,106,310 | |
| Volume/Avg Volume (20 Days) Ratio | 0.59 | |
| 52 Week Range | 72.32 - 105.84 | |
| Price vs 52 Week High | -5.22% | |
| Price vs 52 Week Low | 38.72% | |
| Range | 0.00 | |
| Gap Up/Down | -1.25 | |
Profitibility | ||
| Market Capitalization (Mln) | 215,375 | |
| Revenue per share | 25.7146 | |
| Net Income per share | 7.6197 | |
| Dividend Yield | 0.0327 | |
| Dividend Share | 324.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 12.9946 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
12/12 12:23 EST - fool.com
Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026
One of these pharmaceutical leaders overcame a major obstacle and has a strong outlook. The other is actively pushing greater innovation to get around a rapidly approaching patent cliff.
Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026
One of these pharmaceutical leaders overcame a major obstacle and has a strong outlook. The other is actively pushing greater innovation to get around a rapidly approaching patent cliff.
12/12 11:05 EST - zacks.com
Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?
Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?
Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
12/12 08:45 EST - businesswire.com
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the approval of an expanded indication for WINREVAIR™ (sotatercept), in...
Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the approval of an expanded indication for WINREVAIR™ (sotatercept), in...
12/11 18:46 EST - zacks.com
Merck (MRK) Laps the Stock Market: Here's Why
Merck (MRK) closed at $99.01 in the latest trading session, marking a +1.42% move from the prior day.
Merck (MRK) Laps the Stock Market: Here's Why
Merck (MRK) closed at $99.01 in the latest trading session, marking a +1.42% move from the prior day.
12/10 14:45 EST - marketbeat.com
Dividend Stocks for 2026: Where to Invest as the Market Cools
As we enter the final stretch of 2025, it's clear that this has been a strong year for equities. However, with valuations across the tech sector stretched and talk of an AI-fueled bubble growing louder, many investors are beginning to look for more stable, income-generating opportunities.
Dividend Stocks for 2026: Where to Invest as the Market Cools
As we enter the final stretch of 2025, it's clear that this has been a strong year for equities. However, with valuations across the tech sector stretched and talk of an AI-fueled bubble growing louder, many investors are beginning to look for more stable, income-generating opportunities.
12/10 10:00 EST - fool.com
2 Pharmaceutical Stocks to Buy at a Discount
Weight loss drugs are the big story in the pharmaceutical industry today, but other opportunities exist, too. Bristol Myers Squibb isn't focused on weight loss, has an attractive yield, and continues to cover its dividend.
2 Pharmaceutical Stocks to Buy at a Discount
Weight loss drugs are the big story in the pharmaceutical industry today, but other opportunities exist, too. Bristol Myers Squibb isn't focused on weight loss, has an attractive yield, and continues to cover its dividend.
12/09 17:34 EST - gurufocus.com
Market Today: Fed Cut Looms, Nvidia's China Shift, Target's SoHo Push, OpenAI Taps Slack CEO
Stock News Fed set for âhawkish cut': Goldman Sachs (GS) and other Wall Street desks expect the Federal Reserve to deliver a third straight 25 bps rate cut wh
Market Today: Fed Cut Looms, Nvidia's China Shift, Target's SoHo Push, OpenAI Taps Slack CEO
Stock News Fed set for âhawkish cut': Goldman Sachs (GS) and other Wall Street desks expect the Federal Reserve to deliver a third straight 25 bps rate cut wh
12/09 12:06 EST - zacks.com
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?
Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?
Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.
12/09 11:51 EST - cnbc.com
FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm
The U.S. Food and Drug Administration granted conditional approval for a Merck Animal Health pour-on treatment for the prevention and treatment of New World Screwworm, with farmers able to receive doses by December 20. U.S. cattle herds are at historic lows, pressuring beef prices, with the...
FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm
The U.S. Food and Drug Administration granted conditional approval for a Merck Animal Health pour-on treatment for the prevention and treatment of New World Screwworm, with farmers able to receive doses by December 20. U.S. cattle herds are at historic lows, pressuring beef prices, with the...
12/09 11:15 EST - fool.com
Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump
Merck spent a small fortune on the acquisition of Acceleron Pharma, and so far, it's paying off. Recent phase 2 data suggests the pharmaceutical giant could get even more bang for its buck.
Here's 1 Major Catalyst Behind Merck Stock's Recent 3.8% Bump
Merck spent a small fortune on the acquisition of Acceleron Pharma, and so far, it's paying off. Recent phase 2 data suggests the pharmaceutical giant could get even more bang for its buck.
12/09 10:55 EST - fool.com
1 Major Factor Behind the Healthcare Sector's Recent Surge
Eli Lilly's GLP-1 drug became the world's best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other companies are soaring on new drugs or the growth of existing ones.
1 Major Factor Behind the Healthcare Sector's Recent Surge
Eli Lilly's GLP-1 drug became the world's best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other companies are soaring on new drugs or the growth of existing ones.
12/09 08:00 EST - businesswire.com
BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research
TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a renewed two-year contract with Merck, known as MSD outside of the United States and Canada. “Seeing Merck's teams use ASCEND to unravel disease biology, strengthen...
BenchSci Extends ASCEND Agreement with Merck to Support Preclinical Disease Biology Research
TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a renewed two-year contract with Merck, known as MSD outside of the United States and Canada. “Seeing Merck's teams use ASCEND to unravel disease biology, strengthen...
12/09 07:18 EST - globenewswire.com
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydus”), today jointly announced that they have entered into a strategic partnership for the...
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
PLANEGG-MARTINSRIED, Germany and AHMEDABAD, India, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Formycon AG (FSE: FYB, “Formycon”) and Zydus Lifesciences Limited (including its subsidiaries and affiliates, “Zydus”), today jointly announced that they have entered into a strategic partnership for the...
12/08 09:40 EST - zacks.com
Watch 5 Bigwigs in December After Double-Digit Returns Past Month
Five market giants, CVNA, WMT, AMAT, FCX and MRK, delivered double-digit returns last month with more room to run in December.
Watch 5 Bigwigs in December After Double-Digit Returns Past Month
Five market giants, CVNA, WMT, AMAT, FCX and MRK, delivered double-digit returns last month with more room to run in December.
12/08 03:34 EST - defenseworld.net
Bank of Nova Scotia Trims Position in Merck & Co., Inc. $MRK
Bank of Nova Scotia trimmed its position in shares of Merck and Co., Inc. (NYSE: MRK) by 46.9% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,430,802 shares of the company's stock after selling 1,262,919...
Bank of Nova Scotia Trims Position in Merck & Co., Inc. $MRK
Bank of Nova Scotia trimmed its position in shares of Merck and Co., Inc. (NYSE: MRK) by 46.9% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,430,802 shares of the company's stock after selling 1,262,919...
12/07 08:23 EST - fool.com
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Telecom giant Verizon has the highest yield in the Dow at 6.8%. Energy Goliath Chevron currently offers a hefty 4.6% yield.
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Telecom giant Verizon has the highest yield in the Dow at 6.8%. Energy Goliath Chevron currently offers a hefty 4.6% yield.
12/07 07:30 EST - seekingalpha.com
The Generational Shift I See Now - And My 33 Stocks For What's Coming
I see a generational opportunity in quality stocks, defined by high ROE, stable earnings growth, and low debt. Quality stocks have underperformed AI-driven leaders, creating rare relative value and attractive risk/reward for diversified, income-focused investors. My screen highlights 33 U.S. large...
The Generational Shift I See Now - And My 33 Stocks For What's Coming
I see a generational opportunity in quality stocks, defined by high ROE, stable earnings growth, and low debt. Quality stocks have underperformed AI-driven leaders, creating rare relative value and attractive risk/reward for diversified, income-focused investors. My screen highlights 33 U.S. large...
12/07 07:15 EST - fool.com
Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?
Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning drug. The trading crowd changed its collective mind a couple months ago, sending shares sharply higher.
Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy?
Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning drug. The trading crowd changed its collective mind a couple months ago, sending shares sharply higher.
12/06 08:00 EST - seekingalpha.com
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (December 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (December 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are...
12/05 16:05 EST - fool.com
Do These 3 Healthcare Stocks Need a Checkup?
Pfizer has a sizable 6.8% yield and is down nearly 60% from its 2021 highs. Bristol Myers Squibb has a 5% yield and is off its 2023 highs by nearly 40%.
Do These 3 Healthcare Stocks Need a Checkup?
Pfizer has a sizable 6.8% yield and is down nearly 60% from its 2021 highs. Bristol Myers Squibb has a 5% yield and is off its 2023 highs by nearly 40%.
Market News
×
Loading news…